Warren Buffett, the legendary Oracle of Omaha, has announced he will step down as chairman of Berkshire Hathaway, marking another key stage in the company's long-planned leadership transition. The move is being hailed as a textbook example of corporate succession planning, with Greg Abel expected to take the reins. But as the news ripples through the financial world, a curious group of scientists is whispering a different question: what if this isn't about business at all? At first glance, the announcement seems perfectly harmless. Buffett, 93, has been grooming successors for years, and this is just another box to check. He will remain as CEO, and the transition is expected to be smooth. But consider this: why now? Why would a man who famously said he plans to work "well past 100" suddenly relinquish even a ceremonial title? And why is the story being filed under Science in at least one major news outlet? Here's where the doubt creeps in. If Buffett is simply stepping down, why are leading gerontologists suddenly interested in Berkshire Hathaway's corporate structure? Could it be that the chairman title is not a ceremonial relic, but a biological anchor? Some researchers speculate that Buffett's longevity is not a genetic accident—it's the result of a secret experiment in which the chairmanship itself is a kind of life-support system. By giving it up, he might be testing whether his vitality is tied to the role, like a vampire drawing power from his corporate lair. The consequences of this theory are staggering. If true, Berkshire Hathaway is not a conglomerate; it's a laboratory. Every shareholder meeting becomes a data-collection session, every annual letter a medical report. Greg Abel would not just be a CEO—he'd be a lab technician, tasked with monitoring the vital signs of a man who may or may not be a cyborg. Insurance companies would start pricing premiums based on Berkshire's stock price, and life-extending technologies would be traded on the NYSE under the ticker symbol IMMORT. And what about the other octogenarian billionaires? If Buffett's longevity secret leaks, we could see a wave of corporate restructurings as tech moguls fight over who gets to be chairman of what, hoping to absorb some of that life force. The next time you hear about a CEO "transitioning to executive chairman," don't assume it's about mentorship—it could be a cryogenic handoff. So, as Warren Buffett hands over the chairman's gavel, we have to ask: is he planning for the future of Berkshire, or the future of science? And more importantly, if the chairmanship was keeping him alive, what happens when the next chairman sits in that seat? Will they inherit his wisdom, his fortune, or his biological clock?